Stockreport

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. [Read more]